Results 241 to 250 of about 2,487,415 (296)

SLC25A1 upregulation promotes HNSCC cisplatin resistance via H3K27ac-mediated cellular senescence. [PDF]

NPJ Precis Oncol
Li J, Yang T, Li Y, Yang X, He Y, Yao Y, Zhao S, Liu R, Yang Z, Zhang H, Wang Q, Li H, Wei J.   +12 more
europepmc   +1 more source

DLL1-mediated ferroptosis resistance via the Notch-Nrf2/GPX4 axis drives cisplatin resistance in ovarian cancer. [PDF]

Cancer Metab
Ye D, Huang G, Yan X, Suntan L, Shen H, Shen J.   +5 more
europepmc   +1 more source

Mitochondrial Involvement in Cisplatin Resistance [PDF]

International Journal of Molecular Sciences, 2019
Cisplatin is one of the worldwide anticancer drugs and, despite its toxicity and frequent recurrence of resistance phenomena, it still remains the only therapeutic option for several tumors. Circumventing cisplatin resistance remains, therefore, a major goal for clinical therapy and represents a challenge for scientific research.
Monica Montopoli, Veronica Cocetta, Eugenio Ragazzi   +2 more
exaly   +6 more sources

Some of the next articles are maybe not open access.

Related searches:

Mechanisms of resistance to cisplatin

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2001
The use of cisplatin in cancer chemotherapy is limited by acquired or intrinsic resistance of cells to the drug. Cisplatin enters the cells and its chloride ligands are replaced by water, forming aquated species that react with nucleophilic sites in cellular macromolecules.
M, Kartalou, J M, Essigmann
openaire   +2 more sources

Mechanisms of cellular resistance to cisplatin

Medical Oncology and Tumor Pharmacotherapy, 1988
Treatment of cancer patients often fails because of the resistance in the tumor to chemotherapeutic drugs. A better understanding of mechanisms which are active in resistant cells might lead to measures to circumvent the resistance. This review deals with the mechanisms of action of cisplatin (CDDP) and the various causes for CDDP resistance in the ...
G A, Hospers, N H, Mulder, E G, De Vries
openaire   +2 more sources

Cisplatin resistance and oncogenes - a review

Anti-Cancer Drugs, 2000
Cisplatin is among the most widely used broadly active cytotoxic anticancer drugs; however, its clinical efficacy is often limited by primary or the development of secondary resistance. Several mechanisms have been implicated in cisplatin resistance, including reduced drug uptake, increased cellular thiol/folate levels and increased DNA repair.
W, Dempke, W, Voigt, A, Grothey, B T, Hill, H J, Schmoll   +4 more
openaire   +2 more sources

Cisplatin Resistance and Transcription Factors

Current Medicinal Chemistry-Anti-Cancer Agents, 2005
Cisplatin is one of the most potent and widely used anti-cancer agents in the treatment of various solid tumors. However, the development of resistance to cisplatin is a major obstacle in clinical treatment. Several mechanisms are thought to be involved in cisplatin resistance, including decreased intracellular drug accumulation, increased levels of ...
Takayuki, Torigoe, Hiroto, Izumi, Hiroshi, Ishiguchi, Yoichiro, Yoshida, Mizuho, Tanabe, Takeshi, Yoshida, Tomonori, Igarashi, Ichiro, Niina, Tetsuro, Wakasugi, Takuya, Imaizumi, Yasutomo, Momii, Michihiko, Kuwano, Kimitoshi, Kohno   +12 more
openaire   +2 more sources

The role of microRNA in cisplatin resistance or sensitivity

Expert Opinion on Therapeutic Targets, 2020
Cisplatin is a chemotherapy drug that has been used to treat a number of cancers for decades, and is still one of the most commonly used anti-cancer agents. However, some patients do not respond to cisplatin while other patients who were originally sensitive to cisplatin eventually develop chemoresistance, leading to treatment failure or/and tumor ...
Shanshan, Wang, Ming-Yue, Li, Yi, Liu, Alexander C, Vlantis, Jason Yk, Chan, Lingbin, Xue, Bao-Guang, Hu, Shucai, Yang, Mo-Xian, Chen, Shaoming, Zhou, Wei, Guo, Xianhai, Zeng, Shuqi, Qiu, C Andrew, van Hasselt, Michael Cf, Tong, George G, Chen   +15 more
openaire   +2 more sources

Cisplatin resistance in human cancers

Pharmacology & Therapeutics, 1991
Cancer chemotherapeutic agents primarily act by damaging cellular DNA directly or indirectly. Tumor cells, in contrast to normal cells, respond to cisplatin with transient gene expression to protect and/or repair their chromosomes. Repeated cisplatin treatments results in a stable resistant cell line with enhanced gene expression but lacking gene ...
K J, Scanlon, M, Kashani-Sabet, T, Tone, T, Funato   +3 more
openaire   +2 more sources

Mechanisms of resistance to cisplatin

1991
A number of changes have been detected in cisplatin-resistant cells, some of which are likely to be directly involved in the mechanism of resistance. The four most cited mechanisms are reduced accumulation, increased glutathione, increased metallothionein, and enhanced DNA repair.
openaire   +2 more sources